Coronavirus vaccine
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
1. A pharmaceutical composition comprising an RNA wherein said RNA comprises, from a 5′ to 3′ direction:
(i) a 5′ UTR that comprises a human alpha-globin 5′-UTR;
(ii) a nucleotide sequence that is at least 90% identical to SEQ ID NO: 9, wherein said nucleotide sequence:
(a)includes modified uridines in place of uridines; and
(b) encodes a SARS-CoV-2 Spike (S) polypeptide that is at least 95% identical to SEQ ID NO: 7 and is prefusion stabilized in that it includes at least one proline substitution at position(s) corresponding to position(s) 986 and/or 987 in SEQ ID NO: 7; and
(iii) a 3′-UTR that comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA.
2. The pharmaceutical composition of claim 1 , wherein the RNA comprises a 5′-cap that comprises m2 7,3′-O Gppp(m 1 2′-O )ApG.
3. The pharmaceutical composition of claim 1 , wherein the RNA comprises a polyA sequence, wherein the polyA sequence comprises a sequence that is at least 90% identical to SEQ ID NO: 14, which optionally comprises a modified uridine in place of one or more uridines.
4. The pharmaceutical composition of claim 3 , wherein the 5′-UTR comprises a sequence that is at least 90% identical to SEQ ID NO: 12, which optionally comprises a modified uridine in place of one or more uridines.
5. The pharmaceutical composition of claim 4 , wherein the 3′-UTR comprises a sequence that is at least 90% identical to SEQ ID NO: 13, which optionally comprises a modified uridine in place of one or more uridines.
6. The pharmaceutical composition of claim 1 , wherein the RNA includes modified uridines in place of all uridines.
7. The pharmaceutical composition of claim 6 , wherein the modified uridines are each N1-methyl-pseudouridine.
8. The pharmaceutical composition of claim 1 , wherein the nucleotide sequence of (ii) is characterized in that its G/C content is increased by about 55% as compared to the G/C content of the nucleotide sequence of SEQ ID NO: 2.
9. The pharmaceutical composition of claim 1 , wherein the RNA is formulated in lipid nanoparticles comprising:
(A) a cationically ionizable lipid;
(B) a sterol;
(C) a neutral lipid; and
(D) a polymer conjugated lipid.
10. The pharmaceutical composition of claim 9 , further comprising at least one salt and/or a cryoprotectant.
11. The pharmaceutical composition of claim 10 , wherein the cryoprotectant comprises sucrose.
12. The pharmaceutical composition of claim 9 , wherein the composition is formulated for intramuscular administration.
13. The pharmaceutical composition of claim 9 , wherein the RNA is present in the composition in an amount of about 3 μg per dose, about 10 μg per dose, or about 30 μg per dose.
14. The pharmaceutical composition of claim 1 , wherein the RNA comprises a polyA sequence, wherein the polyA sequence comprises at least 100 adenine nucleotides.
15. The pharmaceutical composition of claim 1 , wherein the modified uridines are each N1-methyl-pseudouridine.
16. A method of vaccinating by administering a pharmaceutical composition comprising an RNA, wherein said RNA comprises, from a 5′ to 3′ direction:
(i) a 5′-UTR that comprises a human alpha-globin 5′-UTR,
(ii) a nucleotide sequence that is at least 90% identical to SEQ ID NO: 9, wherein said nucleotide sequence:
(a) includes modified uridines in place of uridines; and
(b) encodes a SARS-CoV-2 Spike (S) polypeptide that is at least 95% identical to SEQ ID NO: 7 and is prefusion stabilized in that it includes at least one proline substitution at position(s) corresponding to position(s) 986 and/or 987 in SEQ ID NO: 7; and
(iii) a 3′-UTR that comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA.
17. The method of claim 16 , wherein the step of administering comprises administering more than one dose of the pharmaceutical composition.
18. The method of claim 17 , wherein the more than one dose comprises a first dose and at least a second dose, and wherein the first and second doses are spaced apart by a time period of about 21 days.
19. The method of claim 16 , wherein the step of administering comprises administering at least one dose of the pharmaceutical composition, each of which independently comprises RNA in an amount within a range of about 1 μg to about 100 μg.
20. The method of claim 16 , wherein the step of administering comprises administering at least two doses of the pharmaceutical composition, each of which comprises about 30 μg of the RNA.
21. The method of claim 16 , wherein the RNA comprises a nucleotide sequence that is at least 95% identical to SEQ ID NO: 20.
22. The method of claim 21 , wherein the RNA includes modified uridines in place of all uridines.
23. The method of claim 22 , wherein the modified uridines are each N1-methyl-pseudouridine.
24. The method of claim 16 , wherein the modified uridines are each N1-methyl-pseudouridine.
25. The method of claim 16 , wherein the nucleotide sequence of (ii) is SEQ ID NO: 9.
26. The method of claim 16 , wherein the step of administering comprises administering at least one dose of the pharmaceutical composition, each of which independently comprises RNA in an amount within a range of about 10 μg to about 30 μg.
27. The method of claim 16 , wherein the administration is by intramuscular administration.
28. The method of claim 16 , wherein the RNA comprises:
(A) a 5′-cap that comprises m 2 7,3′-O Gppp(m 1 2′-O )ApG; or
(B) a polyA sequence comprising 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence; or
(C) a combination of (A) and (B).
29. The method of claim 16 , wherein the RNA is formulated in lipid nanoparticles comprising:
(A) a cationically ionizable lipid;
(B) a sterol;
(C) a neutral lipid; and
(D) a polymer conjugated lipid.
30. The method of claim 28 , wherein the step of administering comprises administering at least two doses of the pharmaceutical composition.
31. The method of claim 30 , wherein the step of administering comprises administering a subsequent dose of the pharmaceutical composition after the second dose, wherein the subsequent dose is administered at least about 3 months after administering the second dose.
32. The method of claim 16 , further comprising administering a second vaccine.
33. The method of claim 32 , wherein the second vaccine is an influenza vaccine.
34. A method of manufacturing the pharmaceutical composition of claim 1 , comprising combining the RNA with a cationically ionizable lipid, a sterol, a neutral lipid, and a polymer conjugated lipid to form lipid nanoparticles that encapsulate the RNA.
35. The method of claim 34 , wherein the RNA comprises a nucleotide sequence that is at least 95% identical to SEQ ID NO: 20.
36. The method of claim 35 , wherein the nucleotide sequence includes modified uridines in place of all uridines.